ライフサイエンスコーパス: alcoholic hepatitis

1 favored for carefully selected patients with alcoholic hepatitis.

2 patients with fulminant hepatic failure and alcoholic hepatitis.

3 biological markers of deleterious outcome in alcoholic hepatitis.

4 can be recommended as standard therapies for alcoholic hepatitis.

5 remain the cornerstones in the treatment of alcoholic hepatitis.

6 in formulating safe, effective therapies for alcoholic hepatitis.

7 positive cells were also greater in NASH vs. alcoholic hepatitis.

8 re markedly increased in patients with acute alcoholic hepatitis.

9 ssue and serum samples from 54 patients with alcoholic hepatitis.

10 with normal liver 11 pg/mg) in patients with alcoholic hepatitis.

11 timize the therapeutic development in severe alcoholic hepatitis.

12 17 could be a viable approach in attenuating alcoholic hepatitis.

13 ADH-specific cellular immunity is present in alcoholic hepatitis.

14 ne did not improve survival in patients with alcoholic hepatitis.

15 argeted therapies to inhibit Th1 immunity in alcoholic hepatitis.

16 er diseases such as autoimmune hepatitis and alcoholic hepatitis.

17 after liver transplantation in patients with alcoholic hepatitis.

18 l mechanism underlying IL-8 up-regulation in alcoholic hepatitis.

19 m is a potential therapeutic target in acute alcoholic hepatitis.

20 ronic-binge ethanol feeding or patients with alcoholic hepatitis.

21 be an effective treatment for patients with alcoholic hepatitis.

22 effective for the treatment of patients with alcoholic hepatitis.

23 tes to pathogenesis and clinical sequelae of alcoholic hepatitis.

24 of whom 15 had histopathological evidence of alcoholic hepatitis (10 cirrhotic) and 9 no evidence of

25 In patients with alcoholic hepatitis, 4-week treatment with pentoxifyllin

26 epatitis (10 cirrhotic) and 9 no evidence of alcoholic hepatitis (5 cirrhotic); other controls includ

27 or pentoxifylline is recommended for severe alcoholic hepatitis, a life-threatening disease.

28 PTX3 levels were increased in patients with alcoholic hepatitis, a prototypic acute-on-chronic condi

29 ed blood samples from 20 patients with acute alcoholic hepatitis (AAH), 16 patients with stable advan

30 erapy has shown some benefit in severe acute alcoholic hepatitis (AAH); however, this is limited by u

31 Alcoholic hepatitis (AH) develops in only a small propor

32 Alcoholic hepatitis (AH) frequently progresses to multip

33 Severe alcoholic hepatitis (AH) has high mortality.

34 BACKGROUND & AIMS: Patients with severe alcoholic hepatitis (AH) have a high risk of death withi

35 Epidemiologic studies of alcoholic hepatitis (AH) have been hindered by the lack

36 Alcoholic hepatitis (AH) is a distinct spectrum of alcoh

37 Severe alcoholic hepatitis (AH) is a life-threatening disease f

38 Alcoholic hepatitis (AH) is a severe condition developed

39 Alcoholic hepatitis (AH) is a syndrome of jaundice and l

40 Alcoholic Hepatitis (AH) is major source of alcohol-rela

41 Alcoholic hepatitis (AH) is the most severe form of alco

42 Alcoholic hepatitis (AH) is the most severe form of alco

43 sessing severity of disease in patients with alcoholic hepatitis (AH) is useful for predicting mortal

44 The diagnosis of alcoholic hepatitis (AH) often requires a transjugular l

45 Mortality in patients with alcoholic hepatitis (AH) remains high, and although cort

46 Steroids improve the outcome in alcoholic hepatitis (AH), but up to 40% of patients fail

47 the transcriptome analysis of patients with alcoholic hepatitis (AH), osteopontin (OPN) as one of th

48 s on effective therapeutic interventions for alcoholic hepatitis (AH), the most severe form of alcoho

49 crophages are central to the pathogenesis of alcoholic hepatitis (AH).

50 stem to determine prognoses of patients with alcoholic hepatitis (AH).

51 ts based on the diagnosis of the explant (46 alcoholic hepatitis and 138 alcoholic cirrhosis) and dia

52 se (n = 58), 43 had histological features of alcoholic hepatitis and 15 (25%) did not.We aimed to det

53 t both listing as well as of the explant (11 alcoholic hepatitis and 33 alcoholic cirrhosis).

54 Patients with suspected alcoholic hepatitis and a Discriminant Function >/=32 un

55 s, but safe and effective therapies for both alcoholic hepatitis and alcoholic cirrhosis are still wa

56 se but safe and effective therapies for both alcoholic hepatitis and alcoholic cirrhosis have yet to

57 Five-year graft and patient survival of alcoholic hepatitis and alcoholic cirrhosis patients wer

58 oholic cirrhosis were studied, 27 with acute alcoholic hepatitis and cirrhosis, in whom hepatic venou

59 for the development of advanced ALD such as alcoholic hepatitis and cirrhosis.

60 to produce safe and effective therapies for alcoholic hepatitis and for reversing cirrhosis.

61 to determine the likelihood of histological alcoholic hepatitis and guide treatment.

62 n-1alpha in liver samples from patients with alcoholic hepatitis and individuals without alcoholic he

63 e interleukin-8 (IL-8) is highly elevated in alcoholic hepatitis and levels correlate with the degree

64 Patients with a clinical diagnosis of alcoholic hepatitis and severe disease were randomly ass

65 al hepatitis, typically in Asia, and drug or alcoholic hepatitis and variceal hemorrhage in the West.

66 sease, which includes alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis.

67 use results in the development of steatosis, alcoholic hepatitis, and cirrhosis.

68 osis was assessed in NASH, simple steatosis, alcoholic hepatitis, and controls without liver disease

69 e associated with obesity, type II diabetes, alcoholic hepatitis, and nonalcoholic steatohepatitis.

70 ants include bacterial and viral infections, alcoholic hepatitis, and surgery, but in more than 40% o

71 Steroid use and nutrition for alcoholic hepatitis are being refined, and the validity

72 a on liver transplantation for patients with alcoholic hepatitis are limited.

73 ents were stratified into two groups: severe alcoholic hepatitis as first liver decompensation (Group

74 ere heavy drinkers with severe biopsy-proven alcoholic hepatitis, as indicated by recent onset of jau

75 rinking post-OLT, and three of those died of alcoholic hepatitis at nine months, 2.5 and 3.5 years af

76 precipitating event (active alcoholism/acute alcoholic hepatitis, bacterial infection, and others); (

77 short-term and long-term survival in severe alcoholic hepatitis based on baseline disease severity,

78 ted in increasing mortality in patients with alcoholic hepatitis but the underlying mechanisms are no

79 both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit

80 test the hypothesis that LBP is involved in alcoholic hepatitis by comparing LBP knockout and wild-t

81 o patients with a variety of liver diseases (alcoholic hepatitis, cirrhosis, hepatocellular carcinoma

82 blood mononuclear cells of patients with ALD/alcoholic hepatitis compared to controls.

83 alcoholic hepatitis and individuals without alcoholic hepatitis (controls).

84 tocol showed that early transplant in severe alcoholic hepatitis could improve survival with low inci

85 In patients with moderate to severe alcoholic hepatitis, etanercept was associated with a si

86 blood monocytes isolated from patients with alcoholic hepatitis, expression of TNFalpha mRNA was rob

87 ng organ inflammation, including in viral or alcoholic hepatitis, fatty liver disease, allograft reje

88 e spectrum of ALD includes simple steatosis, alcoholic hepatitis, fibrosis, cirrhosis, and superimpos

89 Proliferative anti-ADH immune responses in alcoholic hepatitis focused on individual epitopic regio

90 se patients with a histological diagnosis of alcoholic hepatitis from those without, and assess poten

91 Liver samples from patients with alcoholic hepatitis had reduced levels of SIRT1 and a hi

92 ared with alcoholic cirrhosis, patients with alcoholic hepatitis have similar posttransplantation gra

93 a semiquantitative scoring system called the Alcoholic Hepatitis Histologic Score (AHHS) was develope

94 ommon, however, it was associated with fatal alcoholic hepatitis in 50% of patients.

95 m liver biopsy showed histologic features of alcoholic hepatitis in addition to bridging fibrosis or

96 tion of lipin-1 ameliorated inflammation and alcoholic hepatitis in mice via activation of endocrine

97 levels, and a histologic picture similar to alcoholic hepatitis in the absence of alcohol abuse.

98 In patients with alcoholic hepatitis, increased expression of p21, but no

99 t to transplant selected patients with acute alcoholic hepatitis, initiated in October 2012.

100 Alcoholic hepatitis is a cause of major morbidity and mo

101 Alcoholic hepatitis is a clinical syndrome characterized

102 Acute alcoholic hepatitis is associated with significant lymph

103 Alcoholic hepatitis is characterised by florid hepatic i

104 Acute alcoholic hepatitis is characterized by disproportionate

105 Alcoholic hepatitis is characterized by parenchymal neut

106 in-arginine-methyltransferase-1 increased in alcoholic hepatitis livers.

107 that parenchymal neutrophil infiltration in alcoholic hepatitis may be determined by selective upreg

108 Forty-eight patients with moderate to severe alcoholic hepatitis (Model for End-Stage Liver Disease s

109 PBMCs were collected from 15 patients with alcoholic hepatitis (modified Maddrey's discriminant fun

110 that new therapeutic development for severe alcoholic hepatitis must target liver injury in the shor

111 ach of the histologically confirmed cases of alcoholic hepatitis (n = 43) were compared to those with

112 thrombosis (n = 6), hepatoma (n = 3), florid alcoholic hepatitis (n = 6), and refusal to give consent

113 e treatment of inflammatory diseases such as alcoholic hepatitis, nonalcoholic steatohepatitis, and p

114 For alcoholic hepatitis, nutritional support is the mainstay

115 ion, such as those observed in patients with alcoholic hepatitis or cirrhosis.

116 ) and K2 (OR, 9.280 [95% CI, 0.987-87.250]), alcoholic hepatitis (OR, 7.435 [95% CI, 1.397-39.572]),

117 cterized by liver inflammation, fatty liver, alcoholic hepatitis, or liver cirrhosis.

118 a ADMA and SDMA were significantly higher in alcoholic hepatitis patients and in nonsurvivors.

119 PBMs isolated from alcoholic hepatitis patients had high expression of SIRT

120 Alcoholic hepatitis patients have higher portal pressure

121 , analysis of circulating EVs from plasma of alcoholic hepatitis patients revealed increased numbers

122 ic dimethylarginine (SDMA), are increased in alcoholic hepatitis patients, and determined any relatio

123 findings that are identical to those seen in alcoholic hepatitis; patients with NASH, however, do not

124 icosteroids remain the mainstay treatment in alcoholic hepatitis pending the results from large multi

125 se results indicate that nimodipine prevents alcoholic hepatitis, possibly by inhibition of endotoxin

126 addition to being a potential biomarker for alcoholic hepatitis, PTX3 participates in the wound-heal

127 PBMCs from seven of 15 patients with alcoholic hepatitis recognised one to three ADH peptides

128 The cornerstone of treatment for alcoholic hepatitis remains as it was 40 years ago: abst

129 o patients died of myocardial infarction and alcoholic hepatitis, respectively.

130 alterations in circulating albumin in severe alcoholic hepatitis (SAH) patients and their contributio

131 nfections are common in patients with severe alcoholic hepatitis (SAH), but little information is ava

132 nfections are common in patients with severe alcoholic hepatitis (SAH), but little information is ava

133 rly linked to key clinical symptoms of acute alcoholic hepatitis such as fever, neutrophilia, and was

134 mmatory Th1 responses was more pronounced in alcoholic hepatitis than in alcoholic-related cirrhosis.

135 n the patients with histological features of alcoholic hepatitis than in those without.

136 no impact of the etiology of liver disease (alcoholic hepatitis versus alcoholic cirrhosis) on the g

137 r transplantation for a listing diagnosis of alcoholic hepatitis were matched for age, gender, ethnic

138 onsidered in a select group of patients with alcoholic hepatitis who fail to improve with medical the

139 tment of ArLD and its complications, such as alcoholic hepatitis, will allow a greater proportion of

140 ately differentiate patients with or without alcoholic hepatitis without liver biopsy.